Management of sildenafil treatment failures
- PMID: 17053526
- DOI: 10.1097/01.mou.0000250286.60237.a6
Management of sildenafil treatment failures
Abstract
Purpose of review: Although oral type 5 phosphodiesterase inhibitors are considered as first-line therapy for the majority of causes of erectile dysfunction, because of their high efficacy, ease of use, and acceptable safety profile, there are some who fail to respond, mainly because of end-organ failure. This communication reviews the management of sildenafil failures in light of recent advances.
Recent findings: Sildenafil failures can be attributed to either lack of efficacy or side effects; issues may involve the physician, patient, and his partner. Physicians may contribute to sildenafil failure and discontinuation because of inadequate instructions, lack of adequate follow-up, suboptimal dosing, lack of adequate trial, and insufficient clarification about safety issues. Studies have demonstrated that progression of endothelial dysfunction and diminished cavernosal smooth-muscle content are recognized organic factors which cause end-organ dysfunction and ultimately treatment failure.
Summary: Proper counseling, medication optimization, and modifying associated risk factors can provide success in men who had initially failed sildenafil therapy for erectile dysfunction. Other treatment modalities that may be considered when sildenafil failure occurs include vacuum devices, intraurethral, and intracavernosal administration of vasoactive drugs alone or combined with sildenafil. Penile prosthesis implantation is considered as a last resort, if all first-line and second-line therapies fail.
Similar articles
-
Rationale for combination therapy of intraurethral prostaglandin E(1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy.Int J Impot Res. 2002 Feb;14 Suppl 1:S38-42. doi: 10.1038/sj.ijir.3900795. Int J Impot Res. 2002. PMID: 11850734 Clinical Trial.
-
Sildenafil citrate (Viagra) treatment for erectile dysfunction: An updated profile of response and effectiveness.Int J Impot Res. 2006 Sep-Oct;18(5):423-31. doi: 10.1038/sj.ijir.3901492. Epub 2006 Jun 29. Int J Impot Res. 2006. PMID: 16810179 Review.
-
Update on oral treatments for male erectile dysfunction.J Eur Acad Dermatol Venereol. 2004 May;18(3):267-74. doi: 10.1111/j.1468-3083.2004.00885.x. J Eur Acad Dermatol Venereol. 2004. PMID: 15096134 Review.
-
Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective.Urology. 2006 Sep;68(3 Suppl):47-60. doi: 10.1016/j.urology.2006.05.047. Urology. 2006. PMID: 17011375 Review.
-
Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.Pak J Pharm Sci. 2008 Jul;21(3):275-81. Pak J Pharm Sci. 2008. PMID: 18614424 Clinical Trial.
Cited by
-
Efficacy of Chinese Herbal Medicine Formula in the Treatment of Mild to Moderate Erectile Dysfunction: Study Protocol for a Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.Int J Gen Med. 2023 Nov 24;16:5501-5513. doi: 10.2147/IJGM.S436347. eCollection 2023. Int J Gen Med. 2023. PMID: 38034900 Free PMC article.
-
LIPUS-SCs-Exo promotes peripheral nerve regeneration in cavernous nerve crush injury-induced ED rats via PI3K/Akt/FoxO signaling pathway.CNS Neurosci Ther. 2023 Nov;29(11):3239-3258. doi: 10.1111/cns.14256. Epub 2023 May 8. CNS Neurosci Ther. 2023. PMID: 37157936 Free PMC article.
-
Restoration of Cavernous Veno-Occlusive Function through Chronic Administration of a Jun-Amino Terminal Kinase Inhibitor and a LIM-Kinase 2 Inhibitor by Suppressing Cavernous Apoptosis and Fibrosis in a Rat Model of Cavernous Nerve Injury: A Comparison with a Phosphodiesterase Type 5 Inhibitor.World J Mens Health. 2021 Jul;39(3):541-549. doi: 10.5534/wjmh.200085. Epub 2020 Jul 9. World J Mens Health. 2021. PMID: 32777863 Free PMC article.
-
Extracorporeal Shock Waves Therapy Delivered by Aries Improves Erectile Dysfunction in Spontaneously Hypertensive Rats Through Penile Tissue Remodeling and Neovascularization.Sex Med. 2019 Dec;7(4):441-450. doi: 10.1016/j.esxm.2019.08.006. Epub 2019 Sep 21. Sex Med. 2019. PMID: 31551177 Free PMC article.
-
Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.Drugs Aging. 2018 Mar;35(3):175-187. doi: 10.1007/s40266-018-0528-4. Drugs Aging. 2018. PMID: 29464656 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials